on BIOMERIEUX (EPA:BIM)
BioMérieux Achieves CE Marking for LUMED™ APSS™ to Enhance Antimicrobial Stewardship
bioMérieux has announced the CE marking of LUMED™ APSS™, a clinical decision support system aimed at enhancing antimicrobial stewardship programs (ASP) and improving patient outcomes. This software solution assists healthcare professionals in the accurate and timely management of antimicrobial treatments, addressing the challenge of antimicrobial resistance (AMR), which is a major global health threat.
LUMED™ APSS™ offers a process to continuously evaluate and adjust antimicrobial treatments based on current clinical data, promoting the de-escalation of unnecessary treatments. It includes support and training for seamless integration, tailored to the needs of AMS committees in hospitals.
Developed by Lumed, a company acquired by bioMérieux, LUMED™ solutions aim to optimize antibiotic use, improve patient safety, and reduce healthcare costs. With its deployment now expanded in Europe, the initiative underscores bioMérieux's commitment to combating AMR.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOMERIEUX news